Innoviva Inc (INVA)

$19.77 +0.26 (1.33%)
Market Cap 1.46B
Revenue (ttm) 358.71M
Net Income (ttm) 23.39M
EPS (ttm) N/A
PE Ratio 7.49
Forward PE 9.80
Profit Margin 6.52%
Debt to Equity Ratio 0.25
Volume 380,800
Avg Vol 927,008
Day's Range N/A - N/A
Shares Out 74.77M
Stochastic %K 28%
Beta 0.47
Analysts Sell
Price Target $32.50

Company Profile

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 238 9600
Address:
1350 Old Bayshore Highway, Suite 400, Burlingame, United States
AeroSmith
AeroSmith Dec. 22 at 12:56 PM
$INVA Huge volume on Friday. Looks like a good entry spot here. PE of 14 ½ and a forward PE of 9 ½. Cheap.
0 · Reply
RunnerSignals
RunnerSignals Dec. 17 at 8:28 PM
$INVA $KVYO $IONQ Tech and biotech mashup alert! Growth royalties and quantum dreams collide eyes on these charts https://stocksrunner.com/news/2025-12-17-top-10-trending-stock-upgrades-today
0 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 12:00 PM
HC Wainwright & Co. has adjusted their stance on Innoviva ( $INVA ), setting the rating to Buy with a target price of 45 → 46.
0 · Reply
All4Retiring
All4Retiring Dec. 15 at 9:54 PM
$INVA We should see a nice pop once commercialization path is announced. INVA only has a hospital sales force. I would not be surprised if they sell this asset.
0 · Reply
ninergizer
ninergizer Dec. 15 at 9:31 PM
$INVA Nothing changed for me here. Long and strong : )
0 · Reply
5thElement
5thElement Dec. 15 at 2:42 PM
$INVA I am surprised at the reaction, as gonorrhea is becoming much more difficult to treat due to multi drug resistance strains.
0 · Reply
BarelySocialGator
BarelySocialGator Dec. 15 at 2:10 PM
$INVA I'm shocked. No love for the gonorrhea pill? 💊 😏
1 · Reply
jreddyN
jreddyN Dec. 15 at 7:12 AM
$INVA Undervalue stock
0 · Reply
jreddyN
jreddyN Dec. 14 at 2:56 PM
$INVA
0 · Reply
janed102
janed102 Dec. 13 at 7:24 PM
$INVA Institutions own over 95% of the total outstanding shares of Innoviva Inc. (INVA),
0 · Reply
Latest News on INVA
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

Dec 12, 2025, 4:56 PM EST - 12 days ago

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections

Dec 12, 2025, 1:33 PM EST - 12 days ago

US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

Dec 11, 2025, 6:35 PM EST - 13 days ago

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

Nov 25, 2025, 7:00 AM EST - 4 weeks ago

Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

Nov 5, 2025, 4:05 PM EST - 7 weeks ago

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

Antheia Appoints Eric d'Esparbes as Chief Financial Officer

Oct 21, 2025, 8:00 AM EDT - 2 months ago

Antheia Appoints Eric d'Esparbes as Chief Financial Officer

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

Oct 20, 2025, 8:00 AM EDT - 2 months ago

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

Oct 7, 2025, 8:00 AM EDT - 2 months ago

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

Innoviva, Inc. (INVA) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 4:03 PM EDT - 4 months ago

Innoviva, Inc. (INVA) Presents At Citi's Biopharma Back To School Conference Transcript

Innoviva to Participate in Upcoming Investor Conferences

Aug 26, 2025, 7:00 AM EDT - 4 months ago

Innoviva to Participate in Upcoming Investor Conferences

Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

Aug 13, 2025, 8:00 AM EDT - 4 months ago

Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

Aug 6, 2025, 4:05 PM EDT - 5 months ago

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Jun 12, 2025, 7:00 AM EDT - 6 months ago

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

Jun 10, 2025, 6:00 AM EDT - 7 months ago

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

May 20, 2025, 6:00 AM EDT - 7 months ago

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States

May 20, 2025, 1:15 AM EDT - 7 months ago

Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

May 7, 2025, 4:05 PM EDT - 8 months ago

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Mar 12, 2025, 5:08 PM EDT - 10 months ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

ARMP

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

Mar 5, 2025, 7:00 AM EST - 10 months ago

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Feb 26, 2025, 4:04 PM EST - 10 months ago

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Innoviva: Underappreciated Strength In Hospital Therapeutics

Feb 23, 2025, 1:11 AM EST - 10 months ago

Innoviva: Underappreciated Strength In Hospital Therapeutics

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 6, 2025, 7:00 AM EST - 11 months ago

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Dec 16, 2024, 7:00 AM EST - 1 year ago

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Dec 16, 2024, 1:15 AM EST - 1 year ago

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Innoviva to Participate in the UBS Global Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 1 year ago

Innoviva to Participate in the UBS Global Healthcare Conference

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Nov 6, 2024, 4:05 PM EST - 1 year ago

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

Jun 18, 2024, 1:44 PM EDT - 1 year ago

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

GSK

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

May 8, 2024, 4:05 PM EDT - 1 year ago

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

Innoviva to Participate in the BofA Securities Health Care Conference

May 8, 2024, 7:00 AM EDT - 1 year ago

Innoviva to Participate in the BofA Securities Health Care Conference

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Apr 24, 2024, 7:00 AM EDT - 1 year ago

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Mar 4, 2024, 4:01 PM EST - 1 year ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

ARMP

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

Feb 29, 2024, 4:05 PM EST - 1 year ago

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

10 stocks you can bet on being inflation-proof

Feb 28, 2024, 2:48 PM EST - 1 year ago

10 stocks you can bet on being inflation-proof

AM CW CXW HCC OTTR PCAR RDN

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Nov 1, 2023, 4:15 PM EDT - 2 years ago

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Nov 1, 2023, 4:05 PM EDT - 2 years ago

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Innoviva: A Lot Of Moving Parts

Oct 9, 2023, 1:48 PM EDT - 2 years ago

Innoviva: A Lot Of Moving Parts

Innoviva to Participate in the Cantor Global Healthcare Conference

Sep 19, 2023, 8:30 AM EDT - 2 years ago

Innoviva to Participate in the Cantor Global Healthcare Conference

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

Sep 18, 2023, 8:00 AM EDT - 2 years ago

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

Innoviva Appoints Stephen Basso as Chief Financial Officer

Aug 25, 2023, 4:52 PM EDT - 2 years ago

Innoviva Appoints Stephen Basso as Chief Financial Officer

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Aug 2, 2023, 4:05 PM EDT - 2 years ago

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Jul 11, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference

Jun 6, 2023, 4:05 PM EDT - 2 years ago

Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference

FDA approves Innoviva's bacterial pneumonia treatment

May 23, 2023, 10:32 PM EDT - 2 years ago

FDA approves Innoviva's bacterial pneumonia treatment

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

May 23, 2023, 6:42 PM EDT - 2 years ago

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

AeroSmith
AeroSmith Dec. 22 at 12:56 PM
$INVA Huge volume on Friday. Looks like a good entry spot here. PE of 14 ½ and a forward PE of 9 ½. Cheap.
0 · Reply
RunnerSignals
RunnerSignals Dec. 17 at 8:28 PM
$INVA $KVYO $IONQ Tech and biotech mashup alert! Growth royalties and quantum dreams collide eyes on these charts https://stocksrunner.com/news/2025-12-17-top-10-trending-stock-upgrades-today
0 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 12:00 PM
HC Wainwright & Co. has adjusted their stance on Innoviva ( $INVA ), setting the rating to Buy with a target price of 45 → 46.
0 · Reply
All4Retiring
All4Retiring Dec. 15 at 9:54 PM
$INVA We should see a nice pop once commercialization path is announced. INVA only has a hospital sales force. I would not be surprised if they sell this asset.
0 · Reply
ninergizer
ninergizer Dec. 15 at 9:31 PM
$INVA Nothing changed for me here. Long and strong : )
0 · Reply
5thElement
5thElement Dec. 15 at 2:42 PM
$INVA I am surprised at the reaction, as gonorrhea is becoming much more difficult to treat due to multi drug resistance strains.
0 · Reply
BarelySocialGator
BarelySocialGator Dec. 15 at 2:10 PM
$INVA I'm shocked. No love for the gonorrhea pill? 💊 😏
1 · Reply
jreddyN
jreddyN Dec. 15 at 7:12 AM
$INVA Undervalue stock
0 · Reply
jreddyN
jreddyN Dec. 14 at 2:56 PM
$INVA
0 · Reply
janed102
janed102 Dec. 13 at 7:24 PM
$INVA Institutions own over 95% of the total outstanding shares of Innoviva Inc. (INVA),
0 · Reply
janed102
janed102 Dec. 13 at 7:16 PM
$INVA discounted cash flow
0 · Reply
janed102
janed102 Dec. 13 at 1:58 PM
$INVA old news but interesting https://www.gsk.com/en-gb/media/press-releases/gsk-announces-sale-of-stake-in-innoviva-inc/
0 · Reply
All4Retiring
All4Retiring Dec. 13 at 1:47 PM
$INVA I am trying to make sense of the 2nd half of 26 launch. Thoughts? It doesn’t tale that long to sign a partner.
2 · Reply
janed102
janed102 Dec. 13 at 11:58 AM
$INVA $125 million share repurchase program underway plus royalties from 7 respiratory co-produced products with GSK
0 · Reply
ninergizer
ninergizer Dec. 13 at 9:56 AM
$MIST $INVA both got approval on the same day. Congratulations to both companies!
1 · Reply
ninergizer
ninergizer Dec. 13 at 3:48 AM
$INVA Lets go!! On December 12, 2025, the FDA approved zoliflodacin (Nuzolvence) as a single-dose oral medication for uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years and older weighing at least 77 lbs, Innoviva Specialty Therapeutics announced in a news release.1 Zoliflodacin was well-tolerated in the trial, with no serious adverse events reported. Zoliflodacin was well-tolerated in the trial, with no serious adverse events reported. Zoliflodacin is a spiropyrimidinetrione bacterial type II topoisomerase inhibitor that has demonstrated activity against drug-resistant Neisseria gonorrhoeae. The agent was previously granted Qualified Infectious Disease Product designation by the FDA.
0 · Reply
ninergizer
ninergizer Dec. 13 at 2:33 AM
$ARWR $MIST $INVA
0 · Reply
janed102
janed102 Dec. 13 at 1:52 AM
$INVA remember INVA has a controlling stake in Armata Pharmaceuticals
0 · Reply
janed102
janed102 Dec. 13 at 1:19 AM
$INVA https://www.urologytimes.com/view/fda-approves-zoliflodacin-for-uncomplicated-urogenital-gonorrhea
0 · Reply
All4Retiring
All4Retiring Dec. 12 at 11:07 PM
$INVA Innoviva finally posted an approval for Zoliflodacin on their website https://investor.inva.com/node/20961/pdf
0 · Reply
TwongStocks
TwongStocks Dec. 12 at 10:18 PM
$INVA "The Company plans to commercialize NUZOLVENCE in the second half of 2026, either in collaboration with a commercialization partner or independently. " So no immediate launch. Will have to wait and see if they can find a partner or secure enough funding to launch on their own.
1 · Reply
TwongStocks
TwongStocks Dec. 12 at 10:17 PM
$INVA They finally issued the PR. But at 4:56pm ET on a Friday. https://www.businesswire.com/news/home/20251212683585/en/U.S.-FDA-Approves-NUZOLVENCE-zoliflodacin-a-First-in-Class-Single-dose-Oral-Antibiotic-for-the-Treatment-of-Uncomplicated-Urogenital-Gonorrhea-in-Adults-and-Adolescents
0 · Reply